Specifically, we will focus on treatments for PC with homologous recombination deficiency (HRD), mismatch repair deficiency (MMRd), microsatellite instability (MSI), or elevated tumor mutational burden (TMB), and finally we will review advances in theranostics for the detection and treatment of PC with a focus on prostate-specific membrane antigen (PSMA)-directed therapy. This evidence concerns the gene FOLH1 and mismatch repair cancer syndrome 1.